Clinical trials: Metastatic
Solid Tumors
MSB0011359C (M7824) in Participants With Metastatic or Locally Advanced Solid Tumors
The main purpose of this study was to assess the safety and tolerability of MSB0011359C. Study consists of dose-escalation part and an expansion part in participants with metastatic or locally advanced solid tumors, for which no…
- Trial name
- NCT02699515
- Testing
- MSB0011359C
- Where
- 18 sites in Japan, South Korea and 1 more
- Volunteers
- 114 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
HER-2 Positive Breast Cancer, Estrogen Receptor Positive Breast Cancer
Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer
The primary objective of this study is to demonstrate that the combination of palbociclib with anti-HER2 therapy plus endocrine therapy is superior to anti-HER2-based therapy plus endocrine therapy alone in improving the outcomes…
- Trial name
- PATINA (NCT02947685)
- Testing
- palbociclib, trastuzumab, pertuzumab
- Where
- 108 sites in United States, Australia and 6 more
- Volunteers
- 518 people
- Sponsor
- Alliance Foundation Trials, LLC.
Metastatic Pancreatic Cancer
Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas
This is an open-label, single arm, multi-center, Phase II trial to evaluate the progression free survival in patients with metastatic adenocarcinoma of the pancreas treated with a hedgehog inhibitor (GDC-0449) in combination with…
- Trial name
- NCT01088815
- Testing
- Gemcitabine, nab-Paclitaxel, GDC-0449
- Where
- 3 sites in United States
- Volunteers
- 98 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Metastatic Breast Cancer
PhII ICb With/Without Erbitux in MBC Pts
The purpose of this study is to determine the objective response rates produced by irinotecan and carboplatin therapy with or without Erbitux in patients with Metastatic Breast Cancer.
- Trial name
- CA225200 (NCT00248287)
- Testing
- Irinotecan + Carboplatin, irinotecan + Carboplatin + erbitux
- Where
- 59 sites in United States
- Volunteers
- 154 people
- Sponsor
- US Oncology Research
Transplant; Failure, Kidney, Renal Disease, End Stage
Oral Paricalcitol in Kidney Transplant Recipients
This study is being done to find out whether patients who receive a kidney transplant can benefit from taking the medication paricalcitol (trade name Zemplar®) as compared to kidney transplant recipients not taking this…
- Conditions
- Transplant; Failure, Kidney, Renal Disease, End Stage, Hyperparathyroidism, Secondary
- Trial name
- NCT00587158
- Testing
- Paricalcitol, Corticosteroid Avoidance Immune Suppression Protocol
- Where
- 2 sites in United States
- Volunteers
- 100 people
- Sponsor
- Mayo Clinic
Metastatic Esophageal Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma
Abemaciclib Plus Ramucirumab for Esophageal/Gastroesophageal Junction Ca
CDK4/6 and Cyclin D1 are significantly expressed in approximately 80% of esophageal and gastroesophageal junction tumors suggesting that CDK4/6 inhibition may be a successful strategy in these chemotherapy and immunotherapy…
- Trial name
- NCT04921904
- Testing
- Abemaciclib, Ramucirumab
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Baylor Research Institute
Microsatellite Stable, Mismatch Repair Protein Proficient
Pembrolizumab, Capecitabine, and Bevacizumab for Treating Colorectal Cancer
This phase II trial studies the side effects and best dose of capecitabine when given together with pembrolizumab and bevacizumab, and investigates how well they work in treating patients with microsatellite stable colorectal…
- Conditions
- Microsatellite Stable, Mismatch Repair Protein Proficient, Stage III Colorectal Cancer AJCC v7, Stage IIIB Colorectal Cancer AJCC v7
- Trial name
- NCT03396926
- Testing
- Bevacizumab, Capecitabine, Specimen collection
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- University of California, San Francisco
Non-Small Cell Lung Cancer, NSCLC
A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLC
The purpose of this study is to determine whether the combination of MM-121 plus docetaxel is more effective than docetaxel alone in regards to PFS in patients with heregulin-positive NSCLC.
- Conditions
- Non-Small Cell Lung Cancer, NSCLC, Adenocarcinoma, Heregulin
- Trial name
- SHERLOC (NCT02387216)
- Testing
- MM-121, Docetaxel
- Where
- 35 sites in United States, Canada and 4 more
- Volunteers
- 153 people
- Sponsor
- Elevation Oncology
Non-Squamous Non-Small Cell Lung Cancer
Safety and Efficacy Study of Avastin in Locally Advanced Metastatic or Recurrent Non-small Lung Cancer (NSLC) Participants
The purpose of this non-interventional study is the collection and documentation of data on safety and efficacy of intravenous (IV) bevacizumab (Avastin) in addition to platinum-based chemotherapy for first-line treatment in…
- Trial name
- NCT02596958
- Testing
- Bevacizumab
- Where
- Germany
- Volunteers
- 996 people
- Sponsor
- Hoffmann-La Roche
Metastatic Melanoma
Metronomic Therapy in Patients With Metastatic Melanoma
SUMMARY: Metronomic Therapy in Patients with Metastatic Melanoma: A Phase II Study of Low Dose Vinblastine, Cyclophosphamide, and Dacarbazine. Patients with measurable metastatic melanoma are eligible.
- Trial name
- NCT01542255
- Testing
- vinblastine, Cyclophosphamide, dacarbazine
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Prostate Cancer
A Study of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC)
PSMA ADC 2301 is a Phase 2, open-label, study to assess the anti-tumor activity and tolerability of Prostate Specific Membrane Antigen Antibody Drug Conjugate (PSMA ADC) in two groups of subjects with metastatic…
- Trial name
- NCT01695044
- Testing
- PSMA ADC
- Where
- 36 sites in United States
- Volunteers
- 119 people
- Sponsor
- Progenics Pharmaceuticals, Inc.
Pancreatic Neoplasms
A Randomized Study of Amplimexon (Imexon) With Gemcitabine in Pancreatic Cancer
The purpose of this study is to determine if imexon in combination with gemcitabine could improve overall survival as compared to gemcitabine alone in subjects with pancreatic cancer that has spread to other organs such as the…
- Trial name
- NCT00637247
- Testing
- imexon in combination with gemcitabine
- Where
- 48 sites in United States
- Volunteers
- 142 people
- Sponsor
- AmpliMed Corporation
Thyroid Cancer
An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer
The purpose of this study is to learn how hereditary or sporadic medullary thyroid cancer patients, treated with ZD6474, react to the drug, what happens to ZD6474 in the human body, about the side effects of ZD6474, and if ZD6474…
- Trial name
- NCT00410761
- Testing
- ZD6474 (Vandetanib)
- Where
- 127 sites in United States, Australia and 22 more
- Volunteers
- 331 people
- Sponsor
- Genzyme, a Sanofi Company
Carcinoma, Renal Cell
Pazopanib Versus Sunitinib in the Treatment of Asian Subjects With Locally Advanced and/or Metastatic Renal Cell Carcinoma
This was a randomized, open label, parallel group, Phase II study to evaluate the efficacy and safety of pazopanib compared to sunitinib in Asian subjects with advanced renal cell carcinoma (RCC) who have not received prior…
- Trial name
- NCT01147822
- Testing
- Pazopanib, Sunitinib
- Where
- 21 sites in China, South Korea and 1 more
- Volunteers
- 367 people
- Sponsor
- Novartis Pharmaceuticals
Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma
Olaparib in Combination With Pembrolizumab and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma
In this study, patients with recurrent or metastatic head and neck squamous cell carcinoma will receive first line treatment with olaparib, pembrolizumab, and carboplatin.
- Trial name
- NCT04643379
- Testing
- Olaparib, Pembrolizumab, Carboplatin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Washington University School of Medicine
Breast - Female, Male Breast Cancer
Pilot Study of Paclitaxel Plus Pembrolizumab in Metastatic HER2-Negative Breast Cancer
The primary objective of this study is to assess the safety and feasibility of the following two regimens: Cohort A) phased regimen of pembrolizumab in which paclitaxel is followed by paclitaxel plus pembrolizumab and Cohort B)…
- Trial name
- PePPy (NCT03018080)
- Testing
- Pembrolizumab, Paclitaxel
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Wake Forest University Health Sciences
Colorectal Cancer
Study of Enzastaurin With 5-Fluorouracil/Leucovorin (5-FU/LV) Plus Bevacizumab as Maintenance Regimen Following First Line Therapy for Metastatic Colon Cancer
This study will evaluate the addition of enzastaurin to 5-FU (5-fluorouracil)/LV (leucovorin) plus bevacizumab in the maintenance of best response obtained with 6 cycles of first-line therapy consisting of 5-FU/LV + oxaliplatin…
- Trial name
- NCT00612586
- Testing
- Enzastaurin, Leucovorin (LV), 5-fluorouracil (5-FU)
- Where
- 26 sites in United States, Austria and 4 more
- Volunteers
- 117 people
- Sponsor
- Eli Lilly and Company
Metastatic Melanoma, Locally Advanced Refractory/Recurrent Melanoma
Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors
To determine whether special tumor fighting cells that is taken from participants' tumors and grown in the laboratory and then given back to the participant will fight the participant's cancer when their immune system is…
- Conditions
- Metastatic Melanoma, Locally Advanced Refractory/Recurrent Melanoma, Metastatic Head and Neck Cancer, Locally Advanced Refractory/Recurrent Head and Neck Cancer
- Trial name
- NCT03991741
- Testing
- Autologous Tumor Infiltrating Lymphocytes, High-Dose Interleukin 2
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Gregory Daniels
Breast Cancer Metastatic
A Study Evaluating The PF-03084014 In Combination With Docetaxel In Patients With Advanced Breast Cancer
This study is aimed to determine the tolerability of the PF-03084014 plus docetaxel combination in patients with advanced breast cancer. Preliminary information about the efficacy of the combination will also be collected.
- Trial name
- NCT01876251
- Testing
- PF-03084014, Docetaxel
- Where
- 16 sites in United States, Belgium and 2 more
- Volunteers
- 30 people
- Sponsor
- Pfizer
Colorectal Cancer, Metastatic Cancer
Combination Chemotherapy Before or After Surgery in Treating Patients With Colorectal Cancer With Liver Metastases That Could Be Removed By Surgery
RATIONALE: Drugs used in chemotherapy work in different ways to kill tumor cells or stop them from growing. Giving combination chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue that…
- Trial name
- NCT01189227
- Testing
- Postoperative chemotherapy, Perioperative chemotherapy
- Where
- 283 sites in United States
- Volunteers
- 9 people
- Sponsor
- NSABP Foundation Inc
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.